Objective To explore the effects of mouse nerve growth factor (mNGF) combined with donepezil in the treatment of Alzheimer's disease (AD). Methods A total of 72 AD patients who were admitted to the hospital from April 2016 to August 2019 were enrolled as the research subjects. They were randomly divided into study group and control group, 36 cases in each group. The control group was treated with oral donepezil, while study group was treated with mNGF and donepezil. The cognitive function before and after treatment, contents of serum amyloid beta protein (Aβ1-42), Chitinase protein 40 (YKL-40) and Derived neurotrophic factor (BDNF), and inflammatory factors [C-reactive protein (CRP), interleukin 1-β (IL-1β), tumor necrosis factor α (TNF-α)] were compared between the two groups. The curative effect was analyzed and compared between the two groups. Results After treatment, total response rate of study group was higher than that of control group (77.78% vs 55.56%, P<0.05). After treatment, ADAS-cog score in study group was lower than that in control group, while scores of MMSE and ADL were higher than those in control group (P<0.05). After treatment, levels of Aβ1-42, YKL-40, CRP, IL-1β and TNF-α in study group were lower than those in control group, while BDNF level was higher than that in control group (P<0.05). There was no significant difference in incidence of adverse reaction between the two groups (P>0.05). Conclusion The mNGF combined with donepezil can improve cognitive function of AD patients, reduce the inflammatory factors, which has a certain clinical effect on AD.

Objective This study aims to investigate the diagnosis and prognostic significance of miR-326 in childhood acute lymphoblastic leukemia. Methods 70 blood samples from childhood ALL patients and 30 blood samples from healthy volunteers were collected, and qRT-PCR was adopted to detect the relative expression level of serum miR-326. The ROC curve was used to analyze the diagnostic ability and prognostic value of miR-326 in childhood ALL. At the same time, Kaplan-Meier was also performed to draw survival curves to evaluate the survival of children with ALL patients with different expression levels of miR-326. Results Compared with the control group, the expression of miR-326 in the serum of childhood ALL patients was significantly down-regulated (P<0.05). The ROC curve showed an AUC value of 0.876 for the area under the curve, indicating that miR-326 has a good diagnostic value; overall survival analysis showed that low expression of miR-326 suggested a poor survival rate, and the ROC curve showed an AUC value of 0.909. Analysis of progression-free survival showed that low expression of miR-326 suggested a poor progression-free survival rate, and the ROC curve showed an AUC value of 0.815. This indicated that low expression of miR-326 is associated with a poor prognosis. Conclusion According to the expression of miR-326, it is obvious to distinguish children with ALL from healthy people. In addition, the low expression of miR-326 indicates a poor prognosis in children with ALL. Furthermore, miR-326 can be used as a diagnostic and prognostic marker for childhood ALL.